东方生物(688298) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 reached RMB 95,899.40 million, an increase of 15.83% compared to the previous year [4] - Operating profit was RMB -57,582.18 million, showing a slight improvement of 0.52% year-on-year [4] - Net profit attributable to shareholders of the parent company was RMB -56,361.90 million, a decrease of 6.54% from the previous year [4] - Basic earnings per share were RMB -2.93, down 8.92% compared to the previous year [4] Assets and Equity - Total assets at the end of 2025 were RMB 720,012.62 million, a decline of 11.05% from the beginning of the year [6] - Shareholders' equity attributable to the parent company was RMB 600,253.83 million, down 9.67% from the beginning of the year [6] - The company reported a decrease in net assets per share to RMB 29.77, down 9.67% from the beginning of the year [6] Return on Investment - The weighted average return on net assets was -8.90%, a decrease of 1.36 percentage points year-on-year [4] Factors Affecting Performance - The decline in net profit was attributed to significant investments in technology platform development, foreign exchange losses, and reduced interest income [7] Financial Data Disclaimer - Investors are advised to note that the financial data is preliminary and subject to final audit, with potential discrepancies in the annual report [8]